JUMPCAN(SH:600566)2023-04-17 16:00Financial Performance - The company's revenue for Q1 2023 reached ¥2,388,296,884.09, representing a year-on-year increase of 9.87%[4] - Net profit attributable to shareholders was ¥676,756,832.78, reflecting a growth of 16.44% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥606,066,786.61, up by 20.60% year-on-year[4] - Basic earnings per share were ¥0.739, marking a 13.00% increase year-on-year[4] - The net profit for Q1 2023 was CNY 678,157,318.97, an increase of 16.6% compared to CNY 581,464,766.39 in Q1 2022[17] - Operating profit for Q1 2023 reached CNY 760,336,800.06, up from CNY 610,467,582.49 in the same period last year, reflecting a growth of 24.5%[17] - The total comprehensive income for Q1 2023 was CNY 678,157,318.97, compared to CNY 581,464,766.39 in Q1 2022, indicating a growth of 16.6%[18] Cash Flow and Assets - The net cash flow from operating activities amounted to ¥1,301,524,433.03, an increase of 29.38% from the previous year[4] - The net cash flow from operating activities for Q1 2023 was CNY 1,301,524,433.03, compared to CNY 1,006,008,812.50 in Q1 2022, an increase of 29.4%[20] - The net cash flow from investing activities for Q1 2023 was CNY 1,351,078,226.01, a significant recovery from a negative cash flow of CNY -1,945,146,440.65 in Q1 2022[22] - Total assets at the end of the reporting period were ¥15,770,840,321.03, a rise of 5.27% from the end of the previous year[5] - Current assets totaled ¥11,982,090,810.91 in Q1 2023, compared to ¥11,176,697,649.24 in Q1 2022, indicating a growth of 7.19%[12] - Cash and cash equivalents rose to ¥7,467,759,040.05 in Q1 2023, compared to ¥4,818,940,846.89 in Q1 2022, an increase of 55.06%[12] Shareholder Information - Shareholders' equity attributable to the parent company was ¥12,017,706,574.91, which is a 6.00% increase compared to the previous year[5] - The total number of ordinary shareholders at the end of the reporting period was 40,916[7] - The company's equity attributable to shareholders rose to ¥12,017,706,574.91 in Q1 2023, up from ¥11,337,385,551.34 in Q1 2022, reflecting a growth of 6.02%[14] Costs and Expenses - Total operating costs for Q1 2023 were ¥1,706,503,386.50, up from ¥1,590,955,421.80 in Q1 2022, reflecting a year-over-year increase of 7.29%[15] - The company experienced a decrease in sales expenses to CNY 1,089,196,034.01 in Q1 2023 from CNY 1,055,995,827.32 in Q1 2022, indicating improved cost management[17] - The company reported an increase in research and development expenses to CNY 106,628,822.83 in Q1 2023, up from CNY 94,430,464.49 in Q1 2022, reflecting a commitment to innovation[17] Inventory and Receivables - Inventory increased to ¥497,728,551.00 in Q1 2023 from ¥391,476,724.81 in Q1 2022, marking a significant rise of 27.12%[12] - Accounts receivable decreased to ¥2,245,621,026.01 in Q1 2023 from ¥2,831,658,804.07 in Q1 2022, a decline of 20.69%[12] Regulatory and Reporting Information - The financial report was announced on April 17, 2023, by the board of directors of Hubei Jichuan Pharmaceutical Co., Ltd.[23] - The report does not specify any performance summary, user data, future outlook, or guidance for the upcoming quarters[23] - There is no mention of new product or technology development, market expansion, or mergers and acquisitions in the report[23] - The report indicates that the company is not applicable for the first-time execution of new accounting standards or interpretations affecting the financial statements[23] - The document does not provide specific financial figures or percentage changes related to performance metrics[23] - The company’s management team includes Cao Longxiang, Yan Hongquan, and Xi Jianhong, responsible for accounting work[23] - The report is structured to comply with regulatory requirements for financial disclosures[23] - There are no additional strategic initiatives or changes mentioned in the report[23] - The report concludes without detailed insights into operational performance or market conditions[23]